In Vitro Synergy of Isavuconazole Combined With Colistin Against Common Candida Species

Patrick Schwarz, Ilya Nikolskiy, Anne-Laure Bidaud, Frank Sommer, Gert Bange, Éric DannaouiFrontiers in Cellular and Infection Microbiology 2022 · DOI

Abstract

Interactions of isavuconazole and colistin were evaluated against 57 common Candida strains belonging to the species Candida albicans (n = 10), Candida glabrata (n = 10), Candida kefyr (n = 8), Candida krusei (n = 10), Candida parapsilosis (n = 9), and Candida tropicalis (n = 10) by a broth microdilution checkerboard technique based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methodology for antifungal susceptibility testing. Results were analyzed with the fractional inhibitory concentration index and by the response surface analysis. Interpretation by the fractional inhibitory concentration index showed synergy for 50%, 80%, 90%, and 90% of the C. kefyr, C. krusei, C. glabrata, and C. tropicalis strains, respectively. Combination of isavuconazole with colistin against C. albicans and C. parapsilosis exhibited only indifference for 100% and 90% of the strains, respectively. The results were confirmed by response surface analysis for all species except for C. glabrata, for which an indifferent interaction was found for the majority of strains. Antagonistic interaction was never seen regardless of the interpretation model was used.

Introduction

Invasive candidiasis (fungal bloodstream infection) is a major clinical challenge with a staggering mortality rate of approximately 40%. While Candida albicans remains the most common culprit, non-albicans species like C. glabrata and C. krusei are on the rise. These species are often intrinsically resistant or less susceptible to standard azole antifungals. Developing entirely new antifungal classes is a slow and expensive process; to bridge this gap, researchers are investigating drug repurposing. Colistin, an "old" antibiotic typically used for multidrug-resistant Gram-negative bacteria, is hypothesized to act as a "synergy booster" by disrupting fungal cell membranes, thereby facilitating the entry of antifungals like isavuconazole.

Methods

The study evaluated 57 clinical Candida strains across six species using a broth microdilution checkerboard technique based on EUCAST reference methodology. To interpret drug interactions, the researchers utilized two distinct mathematical models:

  1. Fractional Inhibitory Concentration Index (FICI): A traditional method focusing on minimum inhibitory concentrations (MICs) at specific endpoints.
  2. Response Surface Analysis (RSA): A modern approach evaluating the entire growth landscape across all tested drug concentrations.

Results

Synergy was not universal but was highly prevalent in specific non-albicans species. According to FICI interpretation, synergy was observed in 90% of C. glabrata and C. tropicalis strains, 80% of C. krusei, and 50% of C. kefyr. In contrast, the combination was indifferent for 100% of C. albicans and 90% of C. parapsilosis.

Response surface analysis (RSA) plots illustrating the interaction between isavuconazole (ISA) and colistin (COL) across six Candida species.

In synergistic strains, the geometric mean of the colistin concentration required to inhibit growth dropped from 63.23 µg/ml to 9.93 µg/ml when combined with isavuconazole. A critical finding was the total absence of antagonism across all tested strains and models. However, discrepancies between models were noted; for C. glabrata, the RSA model was more conservative, finding synergy in only 10% of strains compared to the 90% suggested by FICI.

Discussion and Conclusion

The observed synergy likely stems from colistin’s ability to increase fungal membrane permeability, allowing isavuconazole to more effectively inhibit ergosterol synthesis. The species-specific response suggests that structural differences in cell membranes play a significant role in treatment efficacy.

While these in vitro results are promising, clinical application must consider colistin's potential nephrotoxicity. Future research should prioritize in vivo validation in animal models to determine if these synergistic effects translate to living systems. This study highlights the potential of repurposing existing antibiotics to combat increasingly resistant and difficult-to-treat fungal infections.

Summary updated

Abstract

Interactions of isavuconazole and colistin were evaluated against 57 common <i>Candida</i> strains belonging to the species <i>Candida albicans</i> (n = 10), <i>Candida glabrata</i> (n = 10), <i>Candida kefyr</i> (n = 8), <i>Candida krusei</i> (n = 10), <i>Candida parapsilosis</i> (n = 9), and <i>Candida tropicalis</i> (n = 10) by a broth microdilution checkerboard technique based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methodology for antifungal susceptibility testing. Results were analyzed with the fractional inhibitory concentration index and by the response surface analysis. Interpretation by the fractional inhibitory concentration index showed synergy for 50%, 80%, 90%, and 90% of the <i>C. kefyr</i>, <i>C. krusei</i>, <i>C. glabrata</i>, and <i>C. tropicalis</i> strains, respectively. Combination of isavuconazole with colistin against <i>C. albicans</i> and <i>C. parapsilosis</i> exhibited only indifference for 100% and 90% of the strains, respectively. The results were confirmed by response surface analysis for all species except for <i>C. glabrata</i>, for which an indifferent interaction was found for the majority of strains. Antagonistic interaction was never seen regardless of the interpretation model was used.
BibTeX
@inproceedings{schwarz2022vitro,
  author = {Patrick Schwarz and Ilya Nikolskiy and Anne-Laure Bidaud and Frank Sommer and Gert Bange and Éric Dannaoui},
  title = {{In Vitro Synergy of Isavuconazole Combined With Colistin Against Common Candida Species}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2022},
  doi = {10.3389/fcimb.2022.892893},
}
Figure